Sareum Holdings PLC Result of AGM (7374I)

TIDMSAR

RNS Number : 7374I

Sareum Holdings PLC

15 December 2020

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 15 December 2020 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, held its Annual General Meeting ("AGM") today and all resolutions were duly passed on a poll. Details of the proxy voting are shown in the table below.

 
 Ordinary resolutions    Votes For     %    Votes Against   %    Votes Total   % of   Votes Withheld 
                                                                                ISC 
                                                                               Voted 
 
 1. Receive 
  the Annual 
  report and 
  accounts for 
  the Company           236,539,335  99.97     76,912      0.03  236,616,247   7.24      317,483 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 2. Approve 
  the Directors' 
  Remuneration 
  Report                225,264,050  98.71    2,946,682    1.29  228,210,732   6.98     8,722,998 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 3. Re-elect 
  Dr Stephen 
  Parker as a 
  director              225,888,456  95.36   10,980,647    4.64  236,869,103   7.25       64,627 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 4. Re-elect 
  Dr Tim Mitchell 
  as a director         236,331,048  99.77     538,055     0.23  236,869,103   7.25       64,627 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 5. Appoint 
  Shipleys LLP 
  as auditor            236,450,012  99.80     483,718     0.20  236,933,730   7.25         0 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 6. Directors' 
  authority to 
  allot new shares      229,589,440  97.03    7,026,807    2.97  236,616,247   7.24      317,483 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 Special Resolution 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 7. Disapplication 
  of pre-emption 
  rights                229,229,425  96.90    7,322,195    3.10  236,551,620   7.24      382,110 
                        -----------  -----  -------------  ----  -----------  ------  -------------- 
 

ISC - Issued Share Capital

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

For further information, please contact:

 
 Sareum Holdings plc 
  Tim Mitchell, CEO                         01223 497 700 
 Strand Hanson Limited (Nominated 
  Adviser) 
  James Dance / Richard Tulloch             020 7409 3494 
 Hybridan LLP (Nominated Broker) 
  Claire Noyce / John Beresford-Peirse      020 3764 2341 
 Citigate Dewe Rogerson (Financial 
  PR) 
  Mark Swallow/ David Dible                 020 7638 9571 
 

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGKKPBPBBDDOBD

(END) Dow Jones Newswires

December 15, 2020 07:59 ET (12:59 GMT)